Results 1 to 10 of about 104,817 (211)

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β [PDF]

Advanced Science
The ubiquitin‐editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20‐mediated IKK ...
Fan Luo, Ting Yang, Jiaxin Cao, Qun Chen, Zhenhai Lu, Feiteng Lu, Chaozhuo Lin, Zengfei Xia, Yuanzhong Yang, Peng Li, Wenjuan Ma, Min Luo, Rongxin Zhang   +12 more
doaj   +2 more sources

Identification of a signature gene set for oxaliplatin sensitivity prediction in colorectal cancer [PDF]

Frontiers in Oncology
BackgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Oxaliplatin-based chemotherapy is a cornerstone of treatment for many CRC patients; however, the development of chemoresistance severely limits its therapeutic ...
Xiaopeng Zhan, Xinyue Li, Yimin Chu, Ying Xu, Fengli Zhou, Ji Li, Daming Yang, Changping Hu, Haixia Peng, Zhaoxia Wu   +9 more
doaj   +2 more sources

Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells [PDF]

, 2013
Colorectal cancer is the third leading cause of cancer-related mortality in the world-- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP).
A Jemal, A Krueger, A Krueger, A Younes, AR Safa, BR Seo, C Liu, C Odoux, CH Mom, D Atallah, D Mahalingam, DB Longley, E Raymond, FA Greco, GJ Ullenhag, HJ Zeh 3rd, HR Alexander Jr., IA Mawji, IN Lavrik, J Yoo, JA Ubersax, JM Cummins, JW Yu, L Zhang, L Zhao, LR Hafström, LY Dimberg, M Irmler, M Upreti, M Vulfovich, MA Alcala Jr., MJ Lee, P Korkolopoulou, Raffaele A Calogero, S Hegewisch-Becker, S Varghese, Seog-Young Kim, SK Libutti, T Bartke, T Ruers, T Trarbach, TR Wilson, W Gao, X Song, X Song, X Song, Xinxin Song, Y Jin-Song, Y Lin, YJ Lee, YL Zhang, Yong J. Lee, Z El Fajoui   +52 more
core   +18 more sources

Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients

Frontiers in Oncology, 2022
BackgroundAddition of oxaliplatin to adjuvant 5-FU has significantly improved the disease-free survival and served as the first line adjuvant chemotherapy in advanced colorectal cancer (CRC) patients. However, a fraction of patients remains refractory to
Khamushavalli Geevimaan, Khamushavalli Geevimaan, Jing-You Guo, Chia-Ning Shen, Jeng-Kai Jiang, Jeng-Kai Jiang, Cathy S. J. Fann, Ming-Jing Hwang, Jr-Wen Shui, Hsiu-Ting Lin, Mei-Jung Wang, Hsuan-Cheng Shih, Anna Fen-Yau Li, Shih-Ching Chang, Shih-Ching Chang, Shung-Haur Yang, Shung-Haur Yang, Shung-Haur Yang, Jeou-Yuan Chen   +18 more
doaj   +1 more source

Oxaliplatin Depolarizes the IB4– Dorsal Root Ganglion Neurons to Drive the Development of Neuropathic Pain Through TRPM8 in Mice

Frontiers in Molecular Neuroscience, 2021
Use of chemotherapy drug oxaliplatin is associated with painful peripheral neuropathy that is exacerbated by cold. Remodeling of ion channels including TRP channels in dorsal root ganglion (DRG) neurons contribute to the sensory hypersensitivity ...
Bin Wu, Bin Wu, Xiaolin Su, Xiaolin Su, Wentong Zhang, Yi-Hong Zhang, Xinghua Feng, Yong-Hua Ji, Zhi-Yong Tan   +8 more
doaj   +1 more source

Construction and Validation of an Oxaliplatin-Resistant Gene Signature in Colorectal Cancer Patients Who Underwent Chemotherapy

Pharmaceuticals, 2022
Aberrant expression of genes contributes to the chemoresistance of colorectal cancer (CRC) treatment. This study aimed to identify genes associated with the chemoresistance of oxaliplatin-based chemotherapy in CRC patients and to construct a signature ...
Yixin Yin, Siqi Li, Xinqiang Liang, Kezhi Li, Mingzhi Xie, Bangli Hu   +5 more
doaj   +1 more source

MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer

Frontiers in Oncology, 2021
Colorectal cancer is one of the most common malignancies worldwide. Oxaliplatin is the first-line chemotherapeutic agent for the treatment of advanced colorectal cancer. However, acquired resistance to oxaliplatin limits its therapeutic efficacy, and the
Xiao-Lan Qian, Fang Zhou, Song Xu, Jian Jiang, Zhi-Peng Chen, Shao-Kai Wang, Yun Zuo, Chen Ni   +7 more
doaj   +1 more source

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]

, 2015
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim, De Wever, Olivier, Descamps, Benedicte, Gremonprez, Félix, Izmer, Andrei, Vanhaecke, Frank, Vanhove, Christian   +6 more
core   +11 more sources

Oxaliplatin related lncRNAs prognostic models predict the prognosis of patients given oxaliplatin-based chemotherapy

Cancer Cell International, 2023
Background Oxaliplatin-based chemotherapy is the first-line treatment for colorectal cancer (CRC). Long noncoding RNAs (lncRNAs) have been implicated in chemotherapy sensitivity. This study aimed to identify lncRNAs related to oxaliplatin sensitivity and
Qing-nan Zhou, Rong-e Lei, Yun-xiao Liang, Si-qi Li, Xian-wen Guo, Bang-li Hu   +5 more
doaj   +1 more source

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2

Molecular Therapy: Oncolytics, 2021
Although oxaliplatin is an effective chemotherapeutic drug commonly used for colorectal cancer (CRC) treatment, drug resistance usually occurs during the long-term use of it.
Wei Sun, Yang Ge, Junpeng Cui, Yifan Yu, Baolin Liu   +4 more
doaj   +1 more source